Added to YB: 2024-10-14
Pitch date: 2024-10-12
AKBA [bullish]
Akebia Therapeutics, Inc.
-10.61%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Market Cap
$411.3M
Pitch Price
$1.32
Price Target
5.00 (+324%)
Dividend
N/A
EV/EBITDA
11.92
P/E
-23.92
EV/Sales
1.97
Sector
Biotechnology
Category
special_situation
Show full summary:
Akebia Therapeutics: This stock is going up next year... right?
AKBA: FDA-approved oral anemia drug Vafseo launches Jan 2025. 2-year TDAPA pricing advantage. $200M+ sales potential. Current $325M valuation ignores launch upside. Q1 2025 results key catalyst. Risks: slow adoption, pricing pressure post-TDAPA. Analyst targets $5-7.50.
Read full article (21 min)